MannKind presents Afrezza clinical data from three studies
MannKind announced that new data from three different studies of Afrezza Inhalation Powder were released at the American Diabetes Association's 79th Scientific Sessions. In pediatric patients, the rapid rise in insulin concentrations corresponded with early postprandial glucose control within the first hour post-dose. The profile is similar to that previously observed in adults. Consistent with its safety profile in adults, Afrezza was generally well-tolerated in pediatric patients; most treatment emergent adverse events were of mild severity, and no severe hypoglycemia was observed. These data will help guide the finalization of the protocol for a phase 3 safety and efficacy study. MannKind investigators also shared data at an oral presentation using mixed meal tolerance testing to assess glucose control, Afrezza dosing and overall safety in a cohort of individuals with type 1 diabetes. When compared to rapid acting injected insulin, Afrezza provided significantly better glucose control in the first two hours following the meal. Even when adjusting the dose of Afrezza using up to two times the dose of injected insulin aspart, Afrezza treatment was associated with lower rates of overall and level 2 hypoglycemia - an observation that was particularly evident in the late post-meal period.